IMPORTANT DISCLAIMER: Ibogaine is investigational and can cause serious adverse effects, including cardiac arrhythmias. This checklist is educational and does not endorse any clinic or guarantee that ibogaine is appropriate for a particular person.
START WITH THE MEDICAL MODEL, NOT THE AMENITIES
When comparing ibogaine treatment centers, the first questions should be about medical screening, monitoring, emergency capability, and clinical decision-making – not room design, scenery, or testimonials. Ibogaine has documented cardiac and neurologic risks, so the safety infrastructure matters more than the marketing presentation.
A responsible program should be able to explain who is excluded, what testing occurs before treatment, who reviews the results, what monitoring is used during administration, and what happens if a complication develops.
QUESTIONS ABOUT CARDIAC AND MEDICAL SCREENING
- Is a recent ECG required and reviewed by a qualified clinician?
- Are electrolytes, liver function, kidney function, medication interactions, and relevant medical history assessed?
- What conditions automatically exclude a patient?
- Is continuous cardiac monitoring used during the acute treatment period?
- What equipment and trained personnel are available if an arrhythmia or other emergency occurs?
Vague answers such as “we have never had a problem” are not equivalent to a safety protocol. A history of uneventful cases does not eliminate known pharmacologic risk.
QUESTIONS ABOUT PSYCHIATRIC SCREENING AND SUBSTANCE USE
Psychiatric assessment matters because severe depression, suicidality, psychosis, mania, trauma symptoms, and polysubstance use can change both risk and the treatment plan. A program should not treat every applicant as an interchangeable candidate.
For opioid-dependent patients, the transition from opioids to any experimental intervention is clinically complex. Ask how withdrawal, tolerance, medications for opioid use disorder, and overdose prevention are addressed before and after the ibogaine experience.
RED FLAGS IN CLAIMS AND MARKETING
- Guaranteed cure rates or promises that one treatment permanently eliminates addiction.
- Claims that cardiac monitoring is unnecessary for healthy-looking patients.
- Pressure to stop prescribed medications without coordination with the prescribing clinician.
- No clear emergency-transfer relationship or plan.
- Testimonials presented as if they were clinical evidence.
- No structured follow-up or referral plan after discharge.
Recent scientific reviews continue to characterize ibogaine evidence as preliminary and safety concerns as substantial. Marketing should reflect that uncertainty rather than erase it.
DO NOT OVERLOOK AFTERCARE
Even if an acute intervention changes cravings or mood, long-term recovery still requires attention to behavior, relationships, mental health, triggers, housing, work, family systems, and ongoing medical care. Ask what happens after the acute experience and who is responsible for continuing treatment.
A high-quality addiction treatment decision should be based on the whole recovery plan, not only on a single intervention. For many patients, established treatments with a stronger evidence base may be more appropriate.
FREQUENTLY ASKED QUESTIONS
Are all ibogaine treatment centers medically supervised?
No. Staffing, screening, monitoring, and emergency capability can vary widely. Patients should verify specific protocols rather than assume they are standard.
What is the most important safety question to ask?
There is no single question, but cardiac screening and monitoring, medication review, emergency readiness, and clear exclusion criteria are essential areas to examine.
Should a center promise that ibogaine cures addiction?
No responsible provider should guarantee a cure. Addiction outcomes depend on many factors, and current ibogaine evidence remains preliminary.
Does Oceánica provide ibogaine treatment?
This article does not represent Oceánica as an ibogaine provider. Oceánica provides residential addiction and mental health treatment and can help families consider evidence-based treatment options.
Recommended Reading
- Ibogaine Treatment: Pros, Cons, and Evidence
- Ibogaine Treatment Cost
- Treatment Process at Oceánica
- Services and Programs at Oceánica
EXTERNAL REFERENCE LINKS
- FDA – FDA Seeks Public Input to Support Ibogaine Research
- PubMed – Thirty Years of Ibogaine Research
- FDA – Psychedelic Drugs
- Oceánica Conecta
Oceánica is a CARF-accredited residential treatment center in Mazatlán, Mexico. Treatment needs are assessed individually by qualified professionals. This article is informational and not medical advice. Call (213) 527-3377 or visit oceanica-usa.com.





